Labcorp SEC filings, summarized
We read every Labcorp 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track LH in your inbox
Add Labcorp to your watchlist — free, every morning.
Recent filings
Labcorp declares quarterly dividend of $0.72 per share
Labcorp Holdings said on October 21, 2026, that its board declared a cash dividend of $0.72 per share. The dividend will be paid on December 11, 2026, to…
Labcorp sets October 28 date for third-quarter 2026 results
Labcorp will release its third-quarter 2026 financial results before the market opens on October 28, 2026, and host an investor webcast at 9:00 a.m. ET to…
Labcorp Reaffirms Long-Term Outlook Despite Proposed Medicare Rate Cuts
Labcorp said CMS released preliminary Clinical Laboratory Fee Schedule rates for 2027-2029 on September 21, 2026, and warned that the rates could impose…
Labcorp Reaffirms 2026 Guidance and Sets 2029 Growth Outlook
At its September 10, 2026 Investor Day, Labcorp reaffirmed 2026 guidance for revenue of $14.71 billion to $14.83 billion, adjusted EPS of $18.10 to $18.55,…
Labcorp executives to speak at Morgan Stanley healthcare conference
Labcorp said members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on…
Labcorp to outline strategy and financial outlook at September 10 Investor Day
Labcorp will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET, featuring CEO Adam Schechter, CFO Julia Wang and other executives.…
Labcorp’s Megan Bailey to Resign; Brian Caveney to Lead Biopharma Laboratory Services
Megan D. Bailey will resign as Labcorp’s executive vice president and president of Central Laboratories and International effective September 4, 2026.…
Labcorp CEO Adam Schechter sells $1.5M in stock
Adam H. Schechter, President and CEO and a director of Labcorp, sold 4,669 shares of common stock at $320.37 per share on Aug. 11, 2026. The sale was worth…
Labcorp Raises 2026 Guidance After Strong Second-Quarter Results
Labcorp reported second-quarter 2026 revenue of $3.73 billion for the period ended June 30, up 5.8% from a year earlier, while diluted EPS rose to $3.64…
Labcorp ($LH) 8‑K: Term Loan Credit Agreement dated Mar 20, 2026 among Labcorp Holdings and lenders;…
Labcorp ($LH) 8‑K: Term Loan Credit Agreement dated Mar 20, 2026 among Labcorp Holdings and lenders; agents include Wells Fargo (administrative agent),…
LABCORP ($LH) 8-K filed 2026-03-20 — Item 2.03 states it incorporates Item 1.01 by reference re: creation…
LABCORP ($LH) 8-K filed 2026-03-20 — Item 2.03 states it incorporates Item 1.01 by reference re: creation of a direct financial obligation/off‑balance‑sheet…
BREAKING: Labcorp ($LH) CONFIRMED a $750M senior unsecured term loan — fully funded Mar 20, 2026; matures…
BREAKING: Labcorp ($LH) CONFIRMED a $750M senior unsecured term loan — fully funded Mar 20, 2026; matures Mar 20, 2028. Wells Fargo & PNC led the facility.…
Labcorp filed an 8‑K on Feb 17, 2026: Exhibit 99.1 is a press release titled “Labcorp Announces 2025…
Labcorp filed an 8‑K on Feb 17, 2026: Exhibit 99.1 is a press release titled “Labcorp Announces 2025 Fourth Quarter and Full Year Results.” Earnings release…
LabCorp ($LH) filed a Form 8‑K on Feb 17, 2026 reporting Item 2.02 — Results of Operations and Financial…
LabCorp ($LH) filed a Form 8‑K on Feb 17, 2026 reporting Item 2.02 — Results of Operations and Financial Condition. Investors should review the full…
Labcorp ($LH) filed an 8‑K on Feb 9, 2026 furnishing a press release (Exhibit 99.1) and an Inline XBRL…
Labcorp ($LH) filed an 8‑K on Feb 9, 2026 furnishing a press release (Exhibit 99.1) and an Inline XBRL cover page (Exhibit 104). Filing signed by Kathryn W.…
Labcorp ($LH) appointed Dr.
Labcorp ($LH) appointed Dr. Sampson to its Board of Directors; press release issued Feb 9, 2026. The release is attached as Exhibit 99.1 to the Form 8-K and…
Labcorp ($LH) appointed John H.
Labcorp ($LH) appointed John H. Sampson, M.D., Ph.D. to its Board (announced Feb 6; effective Feb 9, 2026) and named him to the Quality & Compliance…
LabCorp ($LH) filed an 8‑K on Jan 29, 2026 disclosing a Second Amendment to its Receivables Purchase…
LabCorp ($LH) filed an 8‑K on Jan 29, 2026 disclosing a Second Amendment to its Receivables Purchase Agreement dated Jan 28, 2026 (Exhibit 10.1). Inline…
LabCorp ($LH) 8-K filed 2026-01-29 — Item 2.03 states the creation of a direct financial…
LabCorp ($LH) 8-K filed 2026-01-29 — Item 2.03 states the creation of a direct financial obligation/off‑balance‑sheet arrangement is incorporated by…
BREAKING: Labcorp ($LH) CONFIRMED amendment to its receivables facility — termination extended to Jan 26,…
BREAKING: Labcorp ($LH) CONFIRMED amendment to its receivables facility — termination extended to Jan 26, 2029, $125M accordion added (raise cap from…